These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8390739)

  • 41. Chronic rejection in kidney transplant patients receiving cytomegalovirus prophylaxis with acyclovir.
    Birkeland SA; Rohr N; Elbirk A; Jørgensen KA
    Transplant Proc; 1995 Jun; 27(3):2040-1. PubMed ID: 7792878
    [No Abstract]   [Full Text] [Related]  

  • 42. Acyclovir prophylaxis for cytomegalovirus in liver transplant recipients.
    Singh N; Yu VL
    J Infect Dis; 1994 Jun; 169(6):1406-7. PubMed ID: 8195627
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients.
    Das A
    Hepatology; 2000 Feb; 31(2):311-7. PubMed ID: 10655251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylaxis versus preemptive therapy for prevention of the consequences of cytomegalovirus infection in transplant recipients: a still unresolved issue.
    Potena L; Grigioni F; Magnani G; Branzi A
    Transplantation; 2009 Jan; 87(2):305-6; author reply 306-7. PubMed ID: 19155991
    [No Abstract]   [Full Text] [Related]  

  • 45. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with oral acyclovir.
    Balfour HH; Fletcher CV; Dunn D
    Transplant Proc; 1991 Apr; 23(2 Suppl 1):17-9. PubMed ID: 1647558
    [No Abstract]   [Full Text] [Related]  

  • 46. Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients.
    Vila A; Guirado LL; Balius A; Díaz M; Baró E; Olaya M; Andrade M; Agraz I; Solá R
    Transplant Proc; 1999 Sep; 31(6):2335-6. PubMed ID: 10500605
    [No Abstract]   [Full Text] [Related]  

  • 47. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens.
    Maurer JR; Snell G; deHoyos A; Kesten S; Winton T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1434-5. PubMed ID: 8382872
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of three cytomegalovirus infection prophylactic regimens in liver transplant recipients.
    Pan SH; Rosenthal P; Howard TK; Podesta LG; Sher L; Makowka L
    Transplant Proc; 1992 Aug; 24(4):1466-7. PubMed ID: 1323153
    [No Abstract]   [Full Text] [Related]  

  • 49. Acyclovir to prevent cytomegalovirus infection after renal transplantation.
    Wong T; Toupance O; Chanard J
    Ann Intern Med; 1991 Jul; 115(1):68. PubMed ID: 1646586
    [No Abstract]   [Full Text] [Related]  

  • 50. Acyclovir for cytomegalovirus infection.
    Selby P; Powles R; Stolle K; Stern H
    Br Med J (Clin Res Ed); 1984 Jul; 289(6439):253. PubMed ID: 6331564
    [No Abstract]   [Full Text] [Related]  

  • 51. Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis.
    Ahmad T; Simmonds M; McIver AG; McGraw ME
    Pediatr Nephrol; 1994 Aug; 8(4):489-91. PubMed ID: 7947045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytomegalovirus infections in transplant patients: methods of prevention of primary cytomegalovirus.
    Bowden RA
    Transplant Proc; 1991 Jun; 23(3 Suppl 3):136-8, discussion 138. PubMed ID: 1648818
    [No Abstract]   [Full Text] [Related]  

  • 53. Acyclovir and ganciclovir in cytomegalovirus.
    Moss GB
    Ann Intern Med; 1994 Sep; 121(5):385. PubMed ID: 8042835
    [No Abstract]   [Full Text] [Related]  

  • 54. Infections in bone marrow transplant recipients.
    van der Meer JW; Guiot HF; van den Broek PJ; van Furth R
    Semin Hematol; 1984 Apr; 21(2):123-40. PubMed ID: 6204385
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of cytomegalic inclusion disease with acyclovir and hyper-immune immunoglobulins in newborn infants].
    Zix C; Hascoet JM
    Arch Fr Pediatr; 1993 Oct; 50(8):724-5. PubMed ID: 8002755
    [No Abstract]   [Full Text] [Related]  

  • 56. Infection in organ-transplant recipients.
    Fishman JA; Rubin RH
    N Engl J Med; 1998 Jun; 338(24):1741-51. PubMed ID: 9624195
    [No Abstract]   [Full Text] [Related]  

  • 57. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation.
    Paya CV; Wiesner RH; Hermans PE; Larson-Keller JJ; Ilstrup DM; Krom RA; Moore SB; Ludwig J; Smith TF
    Hepatology; 1992 Jul; 16(1):66-70. PubMed ID: 1319956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Withdrawal of immunosuppression in liver allograft recipients.
    Padbury RT; Toogood GJ; McMaster P
    Liver Transpl Surg; 1998 May; 4(3):242-8. PubMed ID: 9563967
    [No Abstract]   [Full Text] [Related]  

  • 59. Therapeutic approaches to the control of cytomegalovirus infections.
    Dworsky M; Pass RF; Stagno S; Whitley RJ
    Birth Defects Orig Artic Ser; 1984; 20(1):345-52. PubMed ID: 6329371
    [No Abstract]   [Full Text] [Related]  

  • 60. Cytomegalovirus infection in heart transplant recipients: preliminary results of a controlled trial of intravenous gamma globulin.
    Preiksaitis JK; Rosno S; Rasmussen L; Merigan TC
    J Clin Immunol; 1982 Apr; 2(2 Suppl):36S-41S. PubMed ID: 6177709
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.